All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.

The AML Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your AML Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The AML Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the AML Hub cannot guarantee the accuracy of translated content. The AML Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.
2019-09-23T10:12:14.000Z

Gilteritinib receives positive recommendation from EMA CHMP for the treatment of FLT3-mutated AML

Sep 23, 2019
Share:

Bookmark this article

The European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended that gilteritinib is granted marketing authorization in Europe for the treatment of FLT3-mutated relapsed/refractory (R/R) acute myeloid leukemia (AML).1

Gilteritinib was previously approved for use in the United States (US) by the US Food and Drug Administration (FDA) in November 2018.2 The EMA CHMP undertook this review as part of the accelerated assessment procedure, designed for therapies of major public health interest.1

The approvals are based on the results of the phase III ADMIRAL study (NCT02421939), which is a randomized trial comparing the use of gilteritinib (120mg/day) to salvage chemotherapy (SC) in patients with FLT3-mutated R/R AML. In total, 138 patients were treated with gilteritinib or SC, with gilteritinib administered until unacceptable toxicity or lack of clinical benefit.2

Interim analysis from the study, with a median follow-up of 4.6 months, showed:2

  • Complete response (CR) / CR with partial hematologic recovery (CRh): 21% (n= 29)
  • Within any 56-day baseline period:
    • Of the 106 patients reliant on red blood cell (RBC) and/or platelet transfusions at baseline, 33 became independent of RBC/platelet transfusions
    • Of the 32 patients who were independent of both RBC and platelet transfusions at baseline, 17 remained independent
  • Most common adverse events (AEs) in ≥20% of patients:
    • Myalgia/arthralgia
    • Transaminase increase
    • Fatigue/malaise
    • Fever
    • Noninfectious diarrhea
    • Dyspnea
    • Edema
    • Rash
    • Pneumonia
    • Stomatitis
    • Cough
    • Headache
    • Hypotension
    • Dizziness
    • Vomiting

Expert Opinion

  1. European Medicines Agency. Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 16-19 September 2019. https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-16-19-september-2019 [Accessed 2019 Sep 20]
  2. U.S. Food and Drug Administration. FDA approves gilteritinib for relapsed or refractory acute myeloid leukemia (AML) with a FLT3 mutation. https://www.fda.gov/drugs/fda-approves-gilteritinib-relapsed-or-refractory-acute-myeloid-leukemia-aml-flt3-mutatation [Accessed 2019 Sep 20]

Your opinion matters

Do you intend to implement next generation sequencing for measurable residual disease monitoring in AML patients?
0 votes - 5 days left ...

Newsletter

Subscribe to get the best content related to AML delivered to your inbox